ENSC VS AZN Stock Comparison
Performance
ENSC10/100
10/100
ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
AZN100/100
100/100
AZN returned 6.03% in the last 12 months. Based on SPY's performance of -21.20%, its performance is above average giving it a score of 100 of 100.
Technicals
ENSC25/100
25/100
ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
AZN11/100
11/100
AZN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
ENSC33/100
33/100
ENSC has missed earnings 3 times in the last 20 quarters.
AZN56/100
56/100
AZN has missed earnings 3 times in the last 20 quarters.
Profit
ENSC27/100
27/100
Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.
AZN77/100
77/100
Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
ENSC50/100
50/100
ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
AZN48/100
48/100
AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Analyst Price Targets
ENSC
"Analyst Price Targets" not found for ENSC
AZN85/100
85/100
5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79.
Sentiment
ENSC
"Sentiment" not found for ENSC
AZN70/100
70/100
AZN had a bullish sentiment score of 70.02% across Twitter and StockTwits over the last 12 months. It had an average of 101.58 posts, 140.17 comments, and 324.32 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Ensysce Biosciences, Inc. Common Stock Summary
Nasdaq / ENSC
Healthcare
Biotechnology
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
AstraZeneca PLC Summary
Nasdaq / AZN
Healthcare
Drug Manufacturers - General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ENSC to other companies in the same or a similar industry.